Tratamiento de Neuroblastoma en Israel — obtenga 3 coincidencias personalizadas de clínicas

Israeli medical centers report survival rates reaching 85% for high-risk neuroblastoma patients. Specialized oncology facilities achieve a 90% success rate for general pediatric oncology cases. These outcomes stem from intensive multimodality protocols. Centers integrate advanced immunotherapy and MIBG radiation therapy for precise tumor targeting.

• Success rates: High-risk cases show 85% survival; stage 4 survival reaches 75%.
• Advanced therapies: Centers like Sheba utilize MIBG-scintigraphy and specialized immunotherapy protocols.
• Surgical expertise: Dr. Ronit El Hasid has performed over 300 pediatric bone marrow transplants.
• Global ranking: Sheba Medical Center is ranked 7th globally by Newsweek for 2026.

Bookimed Expert Insight: While survival rates are high across Israel, the logistical density at centers like Sheba is unique. Their neuroblastoma bone marrow transplant package includes a 30-day hospital stay. This extended inpatient period is significantly longer than many international protocols. It ensures maximum safety during the critical post-transplant recovery phase.

Patient Consensus: Parents often highlight the speed of diagnosis and the reassuring precision of nuclear medicine tools like MIBG. They note that having access to world-renowned specialists like Dr. Hana Golan provides immense confidence during complex treatments.

Major Israeli hospitals treating neuroblastoma include Sheba Medical Center, Sourasky (Ichilov), Hadassah, Rambam, and Schneider Children's. These facilities hold Joint Commission International (JCI) accreditation. Leading specialists include Dr. Hana Golan and Prof. Ronit El Hasid, who follow international high-risk protocols and utilize bone marrow transplantation.

• Sheba Medical Center: Ranked 7th globally in 2026 with JCI and ISO certifications.
• Sourasky (Ichilov) Center: Reports a 90% success rate for pediatric oncology treatments.
• Specialist credentials: Dr. Hana Golan leads international ESIOP high-risk neuroblastoma protocols.
• Advanced therapies: Centers offer MIBG therapy, CAR-T cell therapy, and stem cell rescue.

Bookimed Expert Insight: Israeli medical centers demonstrate a significant scale of care, with Sheba Medical Center alone treating over 2 million patients annually. Our data shows that top-tier packages, such as those at Sheba, priced around $160,000 for complex bone marrow transplants, often include 30 hospital days. This extensive inpatient stay is a key differentiator compared to clinics in other regions that may offer shorter initial monitoring periods.

Patient Consensus: Parents emphasize the importance of contacting international coordinators early to manage visas and translations. Families note that while surgical success is high, navigating language barriers is easier when using the dedicated international wings of major centers like Sourasky.

MIBG therapy (131I-MIBG) is available in Israel at major tertiary centers like Sheba Medical Center and Rambam Health Care Campus. Facilities manage radiation safety through lead-lined isolation rooms. Specialized protocols include thyroid protection using potassium iodide. Strict monitoring ensures radioactivity stays within safe limits before patient discharge.

• Radiation shielding: Patients stay in lead-lined rooms to block radioactive emissions.
• Thyroid protection: Potassium iodide medication prevents the thyroid from absorbing radioactive iodine.
• Waste protocols: Facilities treat all bodily fluids and disposable items as radioactive waste.
• Contact safety: Caregivers observation happens through leaded windows in separate clean anterooms.
• Discharge criteria: Patients leave once radiation levels drop below specific safety thresholds.

Bookimed Expert Insight: Israeli oncology centers often integrate MIBG therapy into comprehensive high-risk neuroblastoma protocols. At Sheba Medical Center, for example, Dr. Hana Golan serves as a lead investigator for high-risk ESIOP protocols. This high-level clinical integration means patients receive targeted molecular therapy while staying within standardized European treatment frameworks. Such coordination simplifies the transition between MIBG and other complex phases like bone marrow transplantation.

Patient Consensus: Parents find the separation during the 5–7 day isolation period emotionally difficult but understand the safety need. Patients suggest packing disposable entertainment items and using salivary protectors to manage the physical effects of radiation.

High-risk neuroblastoma treatment in Israel typically spans 15 to 18 months. Patients undergo intensive induction, consolidation, and maintenance phases. Specialized centers like Sheba Medical Center usually complete diagnostics in 3 to 5 days. Treatment involves chemotherapy, surgical resection, and autologous stem cell transplantation.

• Induction phase: Lasts 3 to 5 months with 5 to 8 intensive chemotherapy cycles.
• Hospital stay: Expect 30 days for bone marrow transplants in specialized isolation units.
• Surgical recovery: Primary tumor resection generally requires 5 to 7 days of hospitalization.
• Maintenance phase: Involves approximately 6 months of immunotherapy primarily conducted through outpatient care.

Bookimed Expert Insight: Israeli protocols often integrate autologous stem cell transplantation and immunotherapy into a single consolidated timeline. While a standard hospital stay for transplant is 30 days, centers like Sheba Medical Center manage over 2 million patients annually. Their high volume allows for rapid transitions from intensive inpatient care to daily outpatient monitoring.

Patient Consensus: Families emphasize planning for at least 12 to 18 months in Israel to account for recovery buffers. They recommend bringing comfort items for the child as isolation periods during transplant can be extended.

Israel provides comprehensive support for international families. JCI-accredited centers like Sheba and Sourasky employ English-speaking medical teams. Multidisciplinary care includes personalized nutrition and 24-hour nursing. Families receive dedicated assistance with airport-to-clinic transfers. On-site coordinators bridge language gaps throughout the neuroblastoma treatment journey.

• Medical coordination: English-speaking oncologists and immunologists lead pediatric cases.
• Nursing support: Families have 24-hour access to English-proficient nursing staff.
• Dietary services: Dedicated nutritionists provide personalized meal planning for children.
• Transportation: Packages often include airport-to-clinic transfers for seamless arrival.
• Family lodging: Some centers like Sheba include 30-day hospitalizations in treatment bundles.

Bookimed Expert Insight: While many think of medical care only, Sheba Medical Center bundles include 30 hospital nights. This provides a stable base for families. Coordination often starts before arrival with English-language consultations. Choosing clinics ranked by Newsweek ensures international standards for linguistic and medical support. This structure reduces the logistical burden on parents significantly.

Patient Consensus: Parents find having a dedicated coordinator essential for navigating daily hospital life. They often emphasize that having someone to translate medical details into plain English makes complex procedures feel much more manageable.

Israel actively conducts clinical trials for foreign children with relapsed or refractory neuroblastoma. Leading centers like Sheba Medical Center and Schneider Children’s participate in global research consortiums. These trials often grant international patients access to experimental immunotherapies. This including CAR T-cell therapy and novel drug protocols.

• Available therapies: Trials utilize monoclonal antibodies and personalized drug combinations for high-risk cases.
• Leading institutions: Sheba Medical Center offers Phase 1 and specialized immunotherapy trials.
• Innovative access: Naxitamab and Eflornithine are often available through early clinical protocols.
• Regulatory options: Compassionate use regulations may allow access to investigational drugs for children.

Bookimed Expert Insight: Israeli oncology centers serve over 1.8 million patients annually and maintain a 90% oncology success rate. Our data shows Sheba Medical Center is ranked in the top 10 globally by Newsweek. Dr. Hana Golan personally leads international neuroblastoma protocols at this JCI-accredited facility. This combination of global ranking and leadership ensures high-risk patients receive verified expert care.

Patient Consensus: Parents emphasize that starting the medical review early is vital for trial eligibility. They note having a dedicated case manager helps manage the complex logistics of international treatment.

Children can usually fly 1 to 2 weeks after chemotherapy or minor surgery. Stem cell transplants require longer stays. Flights are safe once blood counts stabilize and doctors confirm medical readiness for travel. Patients must carry a formal discharge letter and detailed medication list.

• Travel timeline: Most children fly 7 to 14 days after routine treatment cycles.
• Transplant recovery: Bone marrow transplants require staying near the clinic for 3 to 6 months.
• Follow-up scans: Schedule MIBG-scintigraphy and CT scans every 1 to 3 months after returning.
• Marker monitoring: Check urine VMA and HVA levels regularly to track the treatment response.
• Local coordination: Your home oncologist should coordinate directly with the Israeli medical team.

Bookimed Expert Insight: Israeli protocols often include MIBG therapy or CAR-T cell trials for high-risk neuroblastoma. These advanced treatments require specific monitoring periods before departure. At Sheba Medical Center, Dr. Hana Golan oversees these complex international protocols. We see that many families choose Sheba because it ranks among the top 10 hospitals globally.

Patient Consensus: Parents emphasize the importance of requesting a flight-ready letter for the airline. They also suggest booking flexible tickets in case blood counts take longer to recover.